Compare Nokia Corp (NOK) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Sanofi SA — how do they compare? Nokia Corp trades at $10.74 (market cap $61.08B), while Sanofi SA trades at $42.96 (market cap $103.41B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.65%). Which is the better fit depends on your goals.
| NOK | SNY | |
|---|---|---|
Market Cap | $61.08B | $103.41B |
Sector | Technology | Health |
52-Week High | $16.83 | $52.34 |
52-Week Low | $4.51 | $41.33 |
Enterprise Value | $59.02B | $123.44B |
Dividend Yield | 1.52% | 5.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.66, up 6.18% today, with a bullish technical signal and strong analyst support. Recent earnings show mixed quarterly beats, while revenue trends stabilize around $20B annually. The company maintains a solid balance sheet with $8.91B cash and reduced debt-to-asset ratio of 9.09 in 2025. Positive news includes AI-driven network expansion and Euro Stoxx 50 reinstatement, though cash flow volatility and competitive pressures persist.
Outlook: Growth is supported by AI infrastructure demand and portfolio diversification, but risks include execution challenges and margin pressures. With 61.5% analyst buy ratings and technical momentum, the stock offers upside potential, though investors should weigh high P/E of 76.42 against earnings consistency and free cash flow trends.
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
